Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.

نویسندگان

  • Ryan D Morin
  • Sarit Assouline
  • Miguel Alcaide
  • Arezoo Mohajeri
  • Rebecca L Johnston
  • Lauren Chong
  • Jasleen Grewal
  • Stephen Yu
  • Daniel Fornika
  • Kevin Bushell
  • Torsten Holm Nielsen
  • Tina Petrogiannis-Haliotis
  • Michael Crump
  • Axel Tosikyan
  • Bruno M Grande
  • David MacDonald
  • Caroline Rousseau
  • Maryam Bayat
  • Pierre Sesques
  • Remi Froment
  • Marco Albuquerque
  • Yury Monczak
  • Kathleen Klein Oros
  • Celia Greenwood
  • Yasser Riazalhosseini
  • Madeleine Arseneault
  • Errol Camlioglu
  • André Constantin
  • Qiang Pan-Hammarstrom
  • Roujun Peng
  • Koren K Mann
  • Nathalie A Johnson
چکیده

PURPOSE Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of patients, and yet little is known about its biology. EXPERIMENTAL DESIGN Using exome sequencing, we characterized the mutation profiles of 38 rrDLBCL biopsies obtained at the time of progression after immunochemotherapy. To identify genes that may be associated with relapse, we compared the mutation frequency in samples obtained at relapse to an unrelated cohort of 138 diagnostic DLBCLs and separately amplified specific mutations in their matched diagnostic samples to identify clonal expansions. RESULTS On the basis of a higher frequency at relapse and evidence for clonal selection, TP53, FOXO1, MLL3 (KMT2C), CCND3, NFKBIZ, and STAT6 emerged as top candidate genes implicated in therapeutic resistance. We observed individual examples of clonal expansions affecting genes whose mutations had not been previously associated with DLBCL including two regulators of NF-κB: NFKBIE and NFKBIZ We detected mutations that may be affect sensitivity to novel therapeutics, such as MYD88 and CD79B mutations, in 31% and 23% of patients with activated B-cell-type of rrDLBCL, respectively. We also identified recurrent STAT6 mutations affecting D419 in 36% of patients with the germinal center B (GCB) cell rrDLBCL. These were associated with activated JAK/STAT signaling, increased phospho-STAT6 protein expression and increased expression of STAT6 target genes. CONCLUSIONS This work improves our understanding of therapeutic resistance in rrDLBCL and has identified novel therapeutic opportunities especially for the high-risk patients with GCB-type rrDLBCL. Clin Cancer Res; 22(9); 2290-300. ©2015 AACR.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bovine Leukaemia Virus onco-protein Tax antigen identification in human lymphomas tissue

Background: Bovine leukaemia virus (BLV) is the primary cause of enzootic bovine leukaemia which belongs to the HTLV/BLV group of oncogenic retroviruses including Human T-cell leukaemia virus types 1, 2, and 3 and simian T-lymphotropic virus. Due to daily consumption of milk, meat and other dairy by-products, a possible role in appearing human cancers can be assumed for BLV. Materials and Metho...

متن کامل

Large B-cell lymphoma in a dog: A cyto-histopathological evaluation and Immunophenotyping according to WHO classification for canine lymphomas

In the present study, we described cyto-histopathological features and immunophenotyping of the large B-cell lymphoma in an 8-year-old mixed breed dog with applying the World Health Organization (WHO) system of classification of canine lymphomas. In fine-needle aspiration (FNA), lymph nodes were involved by neoplastic cells of intermediate to large size with deep blue cytoplasm; consist of cent...

متن کامل

Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.

Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3. Nine (36%) of twenty-five patients achieved CR. Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in f...

متن کامل

Biology of Human Tumors Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of patients, and yet little is known about its biology. Experimental Design: Using exome sequencing, we characterized themutation profiles of 38 rrDLBCL biopsies obtained at the time of progression after immunochemotherapy. To identify genes that may be associated with relapse, we compared the mutation frequ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Clinical cancer research : an official journal of the American Association for Cancer Research

دوره 22 9  شماره 

صفحات  -

تاریخ انتشار 2016